At Denovicon Therapeutics, our goal is to accelerate and improve the development of small-molecule therapeutics by utilizing our decades’ worth of drug discovery expertise, proven computational platform, state-of-the-art hardware infrastructure, and proprietary AI–molecular modeling (hybrid) algorithm. We are currently focused on small-molecule therapies for oncology and immuno-oncology targets.